US › Healthcare

Kymera Therapeutics Inc (KYMR)

US · Healthcare · Biotechnology

$104.39+4.07%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$34.4M
Revenue YoY
+55.5%
Net profit
$-69.2M
Profit YoY
-5.6%
EPS
$-0.71
EPS estimate
$-0.86
Net margin
-201.5%

EPS came in at -0.71 against a street estimate of -0.86 — a beat of 17.4%.

Key statistics

Market cap
$8.51B
Forward P/E
0.0
P/B
5.52
Book value
$18.73
EPS (TTM)
$-3.57
52-week high
$130.05
52-week low
$36.65
50-day MA
$98.06
200-day MA
$82.17
Beta
1.96

Analyst view

Analysts rate Kymera Therapeutics Inc a strong buy (17 buy, 3 hold, 0 sell out of 20) with an average price target of $127.18.

Shareholding

Insiders
2.14%
Institutions
115.71%

Largest institutional holders

FundStake
FMR Inc14.22%
Baker Bros Advisors LP10.52%
venBio Select Advisor LLC9.09%
T. Rowe Price Associates, Inc.7.37%
Bvf Inc6.69%
T. Rowe Price Investment Management,Inc.6.64%
BlackRock Inc6.15%
Atlas Venture Life Science Advisors, LLC5.57%

Recent filings & reports

DocumentDate
Board / officer change · Q3 20262026-07-27
Reg FD disclosure · Q2 20262026-06-25
Shareholder vote results · Q2 20262026-06-24
Board / officer change · Q2 20262026-06-08
Quarterly report · Q1 20262026-04-30
Proxy statement · Q2 20262026-04-29
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kymera Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.